ライフサイエンスコーパス: stable coronary artery disease

1 ssociated with improved clinical outcomes in stable coronary artery disease.

2 timal medical therapy (OMT) in patients with stable coronary artery disease.

3 ombination with platelet-directed therapy in stable coronary artery disease.

4 dogrel in healthy subjects and patients with stable coronary artery disease.

5 e from the marrow, and function in acute and stable coronary artery disease.

6 cute coronary syndromes and in patients with stable coronary artery disease.

7 ioning (PC)-mimetic actions in patients with stable coronary artery disease.

8 inhibition than clopidogrel in patients with stable coronary artery disease.

9 s quantitative differences between acute and stable coronary artery disease.

10 e risk of cardiac events among patients with stable coronary artery disease.

11 have not shown benefits in individuals with stable coronary artery disease.

12 making on revascularization in patients with stable coronary artery disease.

13 lled trial of azithromycin among adults with stable coronary artery disease.

14 of ST segment depression in 17 patients with stable coronary artery disease.

15 mpare for evaluating patients with suspected stable coronary artery disease.

16 ation or against each other in patients with stable coronary artery disease.

17 tcomes for PCI with OMT versus OMT alone for stable coronary artery disease.

18 ux similar to that achieved in patients with stable coronary artery disease.

19 angiography, as compared with patients with stable coronary artery disease.

20 een studied in normal subjects or those with stable coronary artery disease.

21 reproducibility of FFRangio in patients with stable coronary artery disease.

22 st (VKA) in atrial fibrillation patents with stable coronary artery disease.

23 nking about revascularization strategies for stable coronary artery disease.

24 pressure for optimal risk stratification in stable coronary artery disease.

25 r dual antiplatelet therapy in patients with stable coronary artery disease.

26 ed by variations in the medical treatment of stable coronary artery disease.

27 aluation of patients with known or suspected stable coronary artery disease.

28 ing only healthy volunteers or subjects with stable coronary artery disease.

29 FVR for long-term mortality in patients with stable coronary artery disease.

30 tive compared with MT alone in patients with stable coronary artery disease.

31 d optimized medical therapy in patients with stable coronary artery disease.

32 r the clinical work-up of suspected or known stable coronary artery disease, 275 individuals had unde

33 vation acute coronary syndromes (57.4%), and stable coronary artery disease (31.0%).

34 ss-sectional study included 93 patients with stable coronary artery disease (57 males; mean age: 63.5

35 INTERPRETATION: In patients with stable coronary artery disease, addition of rivaroxaban

36 In low-risk patients with stable coronary artery disease, aggressive lipid-lowerin

37 In stable coronary artery disease, an elevated hs-CRP level

38 Through Aggressive Lipid Lowering (IDEAL) in stable coronary artery disease and Aggrastat to Zocor (A

39 Patients with stable coronary artery disease and DM exhibit a burden o

40 ine functioning in unmedicated patients with stable coronary artery disease and exercise-induced isch

41 Twenty-two patients with stable coronary artery disease and exercise-induced ST-s

42 In patients with stable coronary artery disease and functionally signific

43 rdial infarction compared with patients with stable coronary artery disease and healthy subjects.

44 Among patients with documented stable coronary artery disease and in whom no revascular

45 UL trial was a large cohort of patients with stable coronary artery disease and left-ventricular dysf

46 mprove cardiac outcomes in all patients with stable coronary artery disease and left-ventricular syst

47 we tested the hypothesis that patients with stable coronary artery disease and normal or slightly re

48 RP does not appear to identify patients with stable coronary artery disease and preserved ejection fr

49 In patients with stable coronary artery disease and preserved left ventri

50 roET-1), and copeptin, in 3717 patients with stable coronary artery disease and preserved left ventri

51 ctiveness of ACE inhibition in patients with stable coronary artery disease and preserved systolic fu

52 Thirty-four patients with stable coronary artery disease and regional left ventric

53 We hypothesized that in patients with stable coronary artery disease and stenosis, percutaneou

54 hs-CRP to predict outcomes in patients with stable coronary artery disease and the prognostic signif

55 Accordingly, 45 patients with stable coronary artery disease and ventricular dysfuncti

56 atients (aged [+/- SD] 57 +/- 10 years) with stable coronary artery disease and ventricular dysfuncti

57 linical settings, including in patients with stable coronary artery disease and with acute coronary s

58 in the risk stratification of patients with stable coronary artery disease, and several invasive and

59 is effective at treating simple lesions and stable coronary artery disease, but it has yet to be ass

60 d with medical therapy (MT) in patients with stable coronary artery disease, but PCI was guided by an

61 lium-dependent vasodilation in patients with stable coronary artery disease by stimulation of insulin

62 ferentiated from the lesions responsible for stable coronary artery disease by their large necrotic c

63 (MI) (n = 8), unstable angina (UA) (n = 15), stable coronary artery disease (CAD) (n = 17), angiograp

64 sensitivity assay, in low-risk patients with stable coronary artery disease (CAD) and to contrast its

65 beyond 1 year of follow-up in patients with stable coronary artery disease (CAD) are largely unknown

66 jects with acute coronary syndrome (ACS) and stable coronary artery disease (CAD) compared with contr

67 We sought to examine whether patients with stable coronary artery disease (CAD) have increased plat

68 tus by BIVA of 900 consecutive patients with stable coronary artery disease (CAD) immediately before

69 mmation in postmenopausal women with chronic stable coronary artery disease (CAD) on appropriate medi

70 on carotid atherosclerosis in patients with stable coronary artery disease (CAD) on drug therapy.

71 l. provide new data indicating that HDL from stable coronary artery disease (CAD) or acute coronary s

72 dothelial function and exercise tolerance in stable coronary artery disease (CAD) patients has not be

73 5 years of age; mean: 56 +/- 5 years of age) stable coronary artery disease (CAD) patients receiving

74 Stable coronary artery disease (CAD) patients with HTPR

75 y (OMT) in patients with type 2 diabetes and stable coronary artery disease (CAD) prevents major adve

76 es data in patients with type 2 diabetes and stable coronary artery disease (CAD) stratified by detai

77 size, and platelet function in patients with stable coronary artery disease (CAD) taking aspirin and

78 diac and pulmonary function in patients with stable coronary artery disease (CAD) treated with ticagr

79 study design, 33 normotensive patients with stable coronary artery disease (CAD) were treated with i

80 assess in patients with type 2 diabetes and stable coronary artery disease (CAD) whether the risk of

81 st MRI for assessing myocardial viability in stable coronary artery disease (CAD) with left ventricul

82 tients with acute HF (AHF), stable HF (SHF), stable coronary artery disease (CAD) without HF, and hea

83 other than angina-related quality of life in stable coronary artery disease (CAD), suggests that a tr

84 S) and endothelial function in subjects with stable coronary artery disease (CAD).

85 myocardial infarction (MI) in patients with stable coronary artery disease (CAD).

86 rse cardiovascular outcomes in patients with stable coronary artery disease (CAD).

87 ents with acute coronary syndromes (ACS) and stable coronary artery disease (CAD).

88 pendent indicators of risk for patients with stable coronary artery disease (CAD).

89 testing (ETT) was examined in patients with stable coronary artery disease (CAD).

90 was used to measure PDT in 42 patients with stable coronary artery disease (CAD).

91 ome in patients with ischemia and clinically stable coronary artery disease (CAD).

92 event myocardial infarction in patients with stable coronary artery disease (CAD).

93 significant research related to treatment of stable coronary artery disease (CAD).

94 otein (HDL) (HDL-Lp-PLA(2)) in patients with stable coronary artery disease (CAD).

95 k of death and myocardial infarction (MI) in stable coronary artery disease (CAD).

96 and 4 women) and 7 nondiabetic patients with stable coronary artery disease (CAD; median age, 67 y; 4

97 revascularization decisions in patients with stable coronary artery disease could be improved by asse

98 Atrial fibrillation patients with stable coronary artery disease (defined as 12 months fro

99 female patient with history of hypertension, stable coronary artery disease, diabetes type 2 and hype

100 ion, congestive heart failure (NYHA II/III), stable coronary artery disease, diabetes type 2 and hype

101 The majority of Medicare patients with stable coronary artery disease do not have documentation

102 Percutaneous coronary intervention (PCI) for stable coronary artery disease does not reduce the risk

103 In patients with stable coronary artery disease, endothelial function was

104 We analysed data from 22 672 patients with stable coronary artery disease enrolled (from Nov 26, 20

105 In patients with stable coronary artery disease, FFR-guided PCI, as compa

106 rative transfusion strategy in patients with stable coronary artery disease following noncardiac surg

107 We screened patients with stable coronary artery disease for cytochrome P450 (CYP)

108 In patients with stable coronary artery disease for whom PCI was being co

109 e COMPASS trial, of whom 24 824 patients had stable coronary artery disease from 558 centres.

110 xamined patients undergoing elective PCI for stable coronary artery disease from January 1, 2009, thr

111 We measured hs-CRP in 3771 patients with stable coronary artery disease from the Prevention of Ev

112 Small studies in patients with stable coronary artery disease have suggested a worse pr

113 (MI) compared with those from patients with stable coronary artery disease; however, a causal role f

114 In patients with stable coronary artery disease, impaired refCFVR, result

115 Most patients with stable coronary artery disease in New York undergoing ca

116 referred initial treatment for patients with stable coronary artery disease is the best available med

117 Stable coronary artery disease is the most common clinic

118 h platelet-directed therapy in patients with stable coronary artery disease is unknown.

119 ents with coexisting atrial fibrillation and stable coronary artery disease is unresolved, and common

120 In patients with stable coronary artery disease, it remains unclear wheth

121 agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunc

122 Male patients with stable coronary artery disease (n = 19; 62.1 +/- 9.3 yea

123 e compared between men and women with either stable coronary artery disease (n=320) or acute coronary

124 ation myocardial infarction (STEMI, n=16) or stable coronary artery disease (n=44).

125 l Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease; NCT01260584).

126 Patients with stable coronary artery disease on aspirin therapy receiv

127 assessed in 187 patients with type 2 DM and stable coronary artery disease on maintenance aspirin an

128 pirin as Background Therapy in Patients With Stable Coronary Artery Disease [ONSET/OFFSET]; NCT005284

129 andomised trials in which 3389 patients with stable coronary artery disease or a stabilised acute cor

130 in patients undergoing PCI in the setting of stable coronary artery disease or acute coronary syndrom

131 d patients from tertiary care hospitals with stable coronary artery disease or acute coronary syndrom

132 ed LMCA PCI between 2005 and 2014 because of stable coronary artery disease or acute coronary syndrom

133 pacity in control subjects and subjects with stable coronary artery disease or acute coronary syndrom

134 of stress echocardiography in patients with stable coronary artery disease or acute myocardial infar

135 rs in chronic cardiovascular conditions like stable coronary artery disease or chronic heart failure

136 Eligible patients were those with stable coronary artery disease or history of low-risk ac

137 In patients with stable coronary artery disease or low-risk ACS treated w

138 after stopping clopidogrel in patients with stable coronary artery disease or peripheral arterial di

139 -controlled, outpatient trial, patients with stable coronary artery disease or peripheral artery dise

140 tory of ASA sensitivity with known/suspected stable coronary artery disease or presenting with an acu

141 patients receive after being diagnosed with stable coronary artery disease or what the comparative o

142 Sixty-three stable coronary artery disease patients underwent ambula

143 al compared with solely medical treatment in stable coronary artery disease patients.

144 ous studies suggest that among patients with stable coronary artery disease, patients with diabetes m

145 initial management strategy in patients with stable coronary artery disease, PCI did not reduce the r

146 and comprehensive analysis in patients with stable coronary artery disease, PCI, as compared with OM

147 In 1,625 patients with stable coronary artery disease, percutaneous coronary in

148 Among the stable coronary artery disease population (n=2382, 31.4%

149 ll for documenting ischemia in patients with stable coronary artery disease prior to elective percuta

150 rs of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease" published in the January

151 onsmokers (n = 56) and smokers (n = 54) with stable coronary artery disease receiving aspirin therapy

152 08 ambulatory outpatients in California with stable coronary artery disease recruited from the Heart

153 We studied 341 patients with stable coronary artery disease, relatively normal left v

154 nary intervention (PCI) in the management of stable coronary artery disease remains controversial.

155 dial infarction (STEMI) patients and matched stable coronary artery disease (SCAD) controls in order

156 edicts clinical outcomes among patients with stable coronary artery disease (SCAD) treated medically.

157 pirin as Background Therapy in Patients With Stable Coronary Artery Disease) study.

158 In atrial fibrillation patients with stable coronary artery disease, the addition of antiplat

159 l flow reserve with best MT in patients with stable coronary artery disease to assess clinical outcom

160 l, we assigned 4012 patients with documented stable coronary artery disease to receive either 600 mg

161 We randomly assigned 3687 patients with stable coronary artery disease to undergo stenting with

162 Patients with stable coronary artery disease undergoing cardiac cathet

163 cTn is relatively common among patients with stable coronary artery disease undergoing PCI and is an

164 procedural cTn elevation among patients with stable coronary artery disease undergoing PCI are unknow

165 In a prospective study, 85 patients with stable coronary artery disease underwent percutaneous co

166 Forty patients with stable coronary artery disease underwent, in randomized

167 care, an initial investigation of suspected stable coronary artery disease using coronary CTA result

168 ion in patients with atrial fibrillation and stable coronary artery disease warrants reassessment.

169 In 1220 patients with stable coronary artery disease, we assessed the FFR in a

170 Nonculprit plaques in women with stable coronary artery disease were more likely to exhib

171 MD), aspirin-treated patients (N = 110) with stable coronary artery disease were randomized to contin

172 ients with type 2 diabetes mellitus (DM) and stable coronary artery disease while on aspirin and clop

173 ents with acute coronary syndromes (ACS) and stable coronary artery disease who are scheduled for per

174 e, safe, and effective in many patients with stable coronary artery disease who remain symptomatic de

175 We included patients with stable coronary artery disease who underwent intracorona

176 mized, double-blind study, 123 patients with stable coronary artery disease who were taking aspirin t

177 lating microparticles from 176 patients with stable coronary artery disease with and without diabetes

178 ascularization modality should be made as in stable coronary artery disease, with a goal of complete

179 ute coronary syndrome without infarction, or stable coronary artery disease without acute coronary sy

180 Among patients who had stable coronary artery disease without clinical heart fa

181 und therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart fa

182 ed that increases in TR or EDPR gradients in stable coronary artery disease would predict heart failu